Tweets
Congrats to Deborah Veis, MD, PhD, appointed to be the next editor-in-chief of Journal of Bone & Mineral Research Plus (JBMR Plus). Dr Veis is a professor in the Division of Bone & Mineral Diseases at Washington University School of Medicine https://t.co/9aOibSdhqC
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
JRheum review: 40–50% of psoriasis pts have psoriatic nail disease NP). NP is an important predictor of enthesitis, which is associated with the early stages of PsA https://t.co/sEuih3CSgX
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
ICYMI: FDA Approves IVIG in Dermatomyositis
https://t.co/PoHtzDYekk
The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/eAQa2oPOOf
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern).
https://t.co/85zvhk4Poz https://t.co/pb9ABL5O8a
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
ICYMI: Potential Birth Defects with Hydroxychloroquine
HCQ is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
https://t.co/k1LOQvWlVm https://t.co/Ka96e733rp
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
https://t.co/6Dfdnin1aI https://t.co/rJFn9WuCgO
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
https://t.co/22HVA32IAh https://t.co/xZNfepcDLQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Don't forget to register for the ACR Virtual Townhall Wednesday 8/4/21: 7 PM ET
Re: COVID vaccination effectiveness for rheum patients w/real world data
@ACRheum @alhkim @rheum_cat
https://t.co/CKAwSLMv8R
k dao @KDAO2011 ( View Tweet )
5 years ago
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
https://t.co/uv19GSZsBV https://t.co/aSFlV9zeGt
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Article in press:
Can ANCA titers predict relapse in patients with GPA?
Cohort study by @UofT_DoM
- microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse
https://t.co/ks3Gj5iSLR
Seminars in Arthritis and Rheumatism @seminarthrheum ( View Tweet )
5 years ago
Study from the UK BSRBR for #AS & 2043 pts showed 44% w/ at least 1 comorbidity. Each comorbidity was associated w/ 0.40 unit increase in BASDAI and 0.53 in spinal pain. More Dz activity w/ Depression, CHF and peptic ulcer, not CRP/ESR https://t.co/0vAnbjHicw
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
